MedTrace Logo

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

NCT05711719 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-01-27

Study results available
· View outcomes & findings →

Summary

Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging.

Conditions

  • Metabolic Syndrome
  • Coronary Microvascular Dysfunction

Interventions

DRUG

Vericiguat

Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms

DRUG

Placebo

Administered the same way

Sponsors & Collaborators

Principal Investigators

  • Thorsten M Leucker, M.D., Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2025-11-18
Completion
2025-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05711719 on ClinicalTrials.gov